Many have been calling Exubera a bomb since it was introduced. Now the numbers back it up. I don’t know any primary care provider or endocrinologist who is prescribing this:
“Yesterday, Pfizer broke out Exubera sales for the first time, and now we know why it took this long: Exubera only sold $4 million in 2Q. This for a product that has been on the market for six quarters. We thought the number was missing a zero at first; we were at $63M for the quarter.”
…





![Proactive monitoring can prevent emergencies by catching heart signals early [PODCAST]](https://kevinmd.com/wp-content/uploads/unnamed-65-190x100.jpg)
![Why physicians must lead the design of artificial intelligence in health care [PODCAST]](https://kevinmd.com/wp-content/uploads/156891f3-d875-411e-9a3e-c50a13997d53-190x100.jpeg)





![Politics and fear have replaced science in U.S. pain management [PODCAST]](https://kevinmd.com/wp-content/uploads/11c2db8f-2b20-4a4d-81cc-083ae0f47d6e-190x100.jpeg)






